Monitoring Neoadjuvant Chemotherapy Responses with NIR Tomography
使用近红外断层扫描监测新辅助化疗反应
基本信息
- 批准号:8696209
- 负责人:
- 金额:$ 42.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-25 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:American College of Radiology Imaging NetworkBiological MarkersBiopsyBlood VesselsBreastChemotherapy-Oncologic ProcedureClinicalClinical OncologyCollaborationsCollagenComplexDataDiffuseDiseaseDisease-Free SurvivalEngineeringEnrollmentFeasibility StudiesFemale breastFlareFrequenciesFundingFutureGoalsGrantHandHemoglobinImageImage AnalysisIn complete remissionIndividualInfusion proceduresInstitutionInvestigationLaboratoriesLeadLengthLesionLipidsLocationMagnetic Resonance ImagingMammary NeoplasmsMeasuresMedical OncologyMetabolismMonitorNear-Infrared SpectroscopyNeoadjuvant TherapyOpticsOutcomeOxygenPathologicPatientsPhasePositioning AttributePrognostic MarkerPropertyRandomized Clinical TrialsRecoveryResearch InfrastructureResearch PersonnelResectedResolutionScanningSkinSpectrum AnalysisStudy SubjectSurfaceSurgical PathologySystemTechnologyTestingTimeTissuesTranslatingTumor BurdenUnited States National Institutes of HealthValidationWaterWomanWorkbasecancer imagingchemotherapycostdesigndiffuse optical tomographyexperienceimprovedindexinginnovationinstrumentmalignant breast neoplasmneovascularnovel strategiesprognosticpublic health relevanceresponsespectroscopic imagingtissue oxygenationtomographytooltreatment responsetumor
项目摘要
DESCRIPTION (provided by applicant): We hypothesize that a newly redesigned portable tomographic version of Near Infrared Spectroscopy (NIRS), developed and tested at Dartmouth over the past 15 years, can successfully characterize changes in breast tumor vascularity, and potentially cellular metabolism, more accurately and with higher spatial resolution than other NIRS technologies currently under investigation, and is better suited to clinical oncology workflow. NIRS tomography (NIRST) is a unique tool for characterizing tissue composition in the female breast which generates images of total hemoglobin concentration (HbT), tissue oxygen saturation (StO2), water fraction, as well as elastic scattering parameters. Based on results obtained in previous studies, the overall goal of this proposal is to develop and evaluate a portable and compact NIRST system that is expected to quantify changes in HbT, StO2 and water fraction more accurately as early indicators of treatment response of locally advanced breast cancers receiving neoadjuvant chemotherapy (NAC), and will have additional wavelengths enabling the recovery of new images of lipid and collagen content. Comparisons to results obtained with hand- held Diffuse Optical Spectroscopic Imaging (DOSI), which has undergone a recently-completed national multi- center (ACRIN) trial, will occur. The proposed mobile NIRST system will integrate into the workflow of clinical oncology practice to maximize patient accrual and participation in the proposed studies, assess the presence of a flair response, and determine whether prognostic information can be obtained that would influence patient management. After developing and validating the new portable NIRST platform with phantom and normal- subject studies, we will quantitatively assess our hypothesis by 1) imaging the response of tumor vasculature before, during and after infusions associated with different treatment cycles of NAC, and 2) quantify pathological and clinical outcomes of response to NAC, and relate these outcomes to changes in NIRST properties measured at different time points during NAC. The project will extend successful preliminary results obtained in studies supported through completed NIH P01 (P01-CA80139, PI Paulsen) and R21 (CA135303, PI Jiang) grants. It also leverages the extensive infrastructure we have developed for breast cancer imaging where investigators from medical oncology, surgical pathology and biomedical optical engineering have collaborated to develop and evaluate advanced technology for breast cancer imaging for more than a decade.
描述(由申请人提供):我们假设过去 15 年在达特茅斯开发和测试的新设计的便携式近红外光谱 (NIRS) 便携式断层扫描版本可以成功地表征乳腺肿瘤血管分布和潜在细胞代谢的变化,更多比目前正在研究的其他 NIRS 技术更准确且具有更高的空间分辨率,并且更适合临床肿瘤学工作流程。 NIRS 断层扫描 (NIRST) 是一种用于表征女性乳房组织成分的独特工具,可生成总血红蛋白浓度 (HbT)、组织氧饱和度 (StO2)、水分数以及弹性散射参数的图像。根据先前研究获得的结果,该提案的总体目标是开发和评估便携式紧凑型 NIRST 系统,该系统有望更准确地量化 HbT、StO2 和水分数的变化,作为局部晚期乳腺治疗反应的早期指标接受新辅助化疗 (NAC) 的癌症,并将具有额外的波长,能够恢复脂质和胶原蛋白含量的新图像。将与最近完成的国家多中心(ACRIN)试验的手持式漫反射光谱成像(DOSI)获得的结果进行比较。拟议的移动 NIRST 系统将整合到临床肿瘤学实践的工作流程中,以最大限度地提高患者在拟议研究中的应计和参与,评估天赋反应的存在,并确定是否可以获得影响患者管理的预后信息。在通过模型和正常受试者研究开发和验证新的便携式 NIRST 平台后,我们将通过以下方式定量评估我们的假设:1)对与不同 NAC 治疗周期相关的输注之前、期间和之后肿瘤脉管系统的反应进行成像,2)量化NAC 反应的病理和临床结果,并将这些结果与 NAC 期间不同时间点测量的 NIRST 特性的变化联系起来。该项目将扩展通过已完成的 NIH P01(P01-CA80139,PI Paulsen)和 R21(CA135303,PI Jiang)赠款支持的研究中获得的成功初步结果。它还利用了我们为乳腺癌成像开发的广泛基础设施,来自肿瘤内科、外科病理学和生物医学光学工程的研究人员十多年来一直合作开发和评估乳腺癌成像的先进技术。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHUDONG JIANG其他文献
SHUDONG JIANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHUDONG JIANG', 18)}}的其他基金
Concurrent Optical Spectroscopy and Breast MRI to Improve Diagnosis without Contrast Injection
同步光学光谱和乳腺 MRI 无需注射造影剂即可改善诊断
- 批准号:
10402775 - 财政年份:2019
- 资助金额:
$ 42.37万 - 项目类别:
Concurrent Optical Spectroscopy and Breast MRI to Improve Diagnosis without Contrast Injection
同步光学光谱和乳腺 MRI 无需注射造影剂即可改善诊断
- 批准号:
9816241 - 财政年份:2019
- 资助金额:
$ 42.37万 - 项目类别:
Monitoring Neoadjuvant Chemotherapy Responses with NIR Tomography
使用近红外断层扫描监测新辅助化疗反应
- 批准号:
9235258 - 财政年份:2014
- 资助金额:
$ 42.37万 - 项目类别:
NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo
乳腺肿瘤体内新辅助化疗反应的近红外缺氧成像
- 批准号:
7739550 - 财政年份:2009
- 资助金额:
$ 42.37万 - 项目类别:
Pressure-enhanced near-infrared breast cancer imaging
压力增强近红外乳腺癌成像
- 批准号:
6870028 - 财政年份:2005
- 资助金额:
$ 42.37万 - 项目类别:
Pressure-enhanced near-infrared breast cancer imaging
压力增强近红外乳腺癌成像
- 批准号:
7344778 - 财政年份:2005
- 资助金额:
$ 42.37万 - 项目类别:
Pressure-enhanced near-infrared breast cancer imaging
压力增强近红外乳腺癌成像
- 批准号:
7020651 - 财政年份:2005
- 资助金额:
$ 42.37万 - 项目类别:
Pressure-enhanced near-infrared breast cancer imaging
压力增强近红外乳腺癌成像
- 批准号:
7189039 - 财政年份:2005
- 资助金额:
$ 42.37万 - 项目类别:
相似国自然基金
膝关节软骨退变多模态磁共振成像与软骨及滑膜相关生物标记物表达关系的实验研究
- 批准号:82360339
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
一种用于生物呼吸标记物检测的中红外全固态超短脉冲激光器的研究
- 批准号:62305188
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
脑出血后迟发性认知功能减退的机制探索和生物标记物研发
- 批准号:82371302
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
纳米孔光电检测泪液双重生物标记物及其在糖尿病视网膜病变无创诊断中的应用研究
- 批准号:22304134
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于HRMS组学研究帕金森病伴RBD的新型生物标记物及代谢网络调控
- 批准号:32220103006
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer
确定早期三阴性乳腺癌的最佳放疗剂量和分割与术前免疫化疗相结合
- 批准号:
10512391 - 财政年份:2023
- 资助金额:
$ 42.37万 - 项目类别:
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
蛋白质组学研究以了解免疫疗法耐药的机制和驱动因素
- 批准号:
10647807 - 财政年份:2022
- 资助金额:
$ 42.37万 - 项目类别:
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
蛋白质组学研究以了解免疫疗法耐药的机制和驱动因素
- 批准号:
10459949 - 财政年份:2022
- 资助金额:
$ 42.37万 - 项目类别:
A DNA Methylation Test for Guiding Lung Cancer Screening
指导肺癌筛查的 DNA 甲基化测试
- 批准号:
10242473 - 财政年份:2021
- 资助金额:
$ 42.37万 - 项目类别:
Role of ctDNA change as a response measure in the EA1183 patient population and how ctDNA changes correlate with metabolic response by serial FDG PET/CT
ctDNA 变化作为 EA1183 患者群体反应指标的作用以及 ctDNA 变化如何与连续 FDG PET/CT 的代谢反应相关
- 批准号:
10671013 - 财政年份:2021
- 资助金额:
$ 42.37万 - 项目类别: